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Abstract
Purpose High-intensity focused ultrasound (HIFU/FUS) has expanded as a noninvasive quantifiable option for hyper-
thermia (HT). HT in a temperature range of 40–47°C (thermal dose CEM43≥ 25) could work as a sensitizer to radiation
therapy (RT). Here, we attempted to understand the tumor radiosensitization effect at the cellular level after a combination
treatment of FUS+RT.
Methods An in vitro FUS system was developed to induce HT at frequencies of 1.147 and 1.467MHz. Human head and
neck cancer (FaDU), glioblastoma (T98G), and prostate cancer (PC-3) cells were exposed to FUS in ultrasound-penetrable
96-well plates followed by single-dose X-ray irradiation (10Gy). Radiosensitizing effects of FUS were investigated by
cell metabolic activity (WST-1 assay), apoptosis (annexin V assay, sub-G1 assay), cell cycle phases (propidium iodide
staining), and DNA double-strand breaks (γH2A.X assay).
Results The FUS intensities of 213 (1.147MHz) and 225W/cm2 (1.467MHz) induced HT for 30min at mean temperatures
of 45.20± 2.29°C (CEM43= 436± 88) and 45.59± 1.65°C (CEM43= 447± 79), respectively. FUS improves the effect of
RT significantly by reducing metabolic activity in T98G cells 48h (RT: 96.47± 8.29%; FUS+RT: 79.38± 14.93%; p= 0.012)
and in PC-3 cells 72h (54.20± 10.85%; 41.01± 11.17%; p= 0.016) after therapy, but not in FaDu cells. Mechanistically,
FUS+RT leads to increased apoptosis and enhancement of DNA double-strand breaks compared to RT alone in T98G and
PC-3 cells.
Conclusion Our in vitro findings demonstrate that FUS has good potential to sensitize glioblastoma and prostate cancer
cells to RT by mainly enhancing DNA damage.
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High-intensity focused ultrasound (HIFU) or focused ultra-
sound (FUS) plays an increasing role in medical applica-
tions because of thermal and mechanical effects on cells,
biological molecules, and tissue, thus expanding the tradi-
tional application of ultrasound in diagnostic imaging to
therapeutic applications [1, 2]. Various magnetic resonance
imaging (MRI)- and ultrasound imaging (US)-guided HIFU
systems are CE marked and approved by the FDA (Food
and Drug Administration) for treatment of benign uterus
myomas, ablation of prostate tissue, palliative pain man-
agement of bone metastasis, and neurological indications
like essential tremor [3, 4]. While hyperthermia (HT) and
tissue ablation with HIFU/FUS are technically feasible ther-
apeutic methods [5], there is great potential with low FUS
intensity less than 5W/cm2 for FUS-mediated delivery of
therapeutic agents [6–9] including chemotherapeutics, ge-
netic material [10], proteins, and small molecules to cells
and solid tumors [11]. FUS can deliver various levels of
acoustic energy at desired sites in the body with minimal
damage to tissue adjacent to the target. As mentioned above,
MRI-guided HIFU/FUS enables not only the generation of
high temperatures (>55°C) to induce coagulation and tissue
necrosis, but it also provides a method to generate quantifi-
able and local HT (40–47°C) in the target area [12].
In oncology, surgery, image-guided ablation, local radi-
ation therapy (RT), and systemic chemotherapeutics are the
four clinical treatment modalities, but all are accompanied
by significant adverse effects [13, 14]. RT commonly used
in the management of head and neck tumors causes skin
burns and affects voice, jawbone, and teeth [15]. Glioblas-
toma is highly resistant to clinical radio- and chemother-
apy and is often inoperable, leading to low survival rates
[16, 17]. Thermal ablation is usually not applicable either.
Prostate cancer is the most common cancer in males in
Europe and metastatic prostate cancer can lead to incapaci-
tating pain and fractures. As examples of highly aggressive
cancer entities, head and neck tumors, glioblastoma, and
metastatic prostate cancer subtypes require novel and more
effective treatment regimens, and were thereby chosen in
our study.
To enhance the treatment outcome, reduce radiation
dose, and simultaneously avoid radiation-induced adverse
effects, growing interest lies on the radiosensitization of
the tumor cells. Heating of tumor cells up to high temper-
atures (40–47°C) in a thermal dose cumulative equivalent
minutes at 43°C (CEM43) range of 25–200min showed
beneficial radiosensitizing effects [12, 18]. The underlying
mechanism of RT is the induction of DNA double-strand
breaks leading to cell death [19]. Application of HT was
reported to increase the tumor radiosensitivity by enhancing
DNA damage, inhibition of DNA repair mechanism, and
reduction of hypoxia [20, 21]. Different mechanisms like
induction of apoptosis mediated by an inhibition of heat
shock proteins [22, 23] or directly by damage of DNA [24]
are also described as leading to radiosensitization effects.
Currently, HT is mostly delivered by microwave, ra-
diofrequency, or FUS in clinic. Microwave and radiofre-
quency generate heating by electromagnetic waves caus-
ing rotation of water molecules in cells, inducing frictional
heating [25]. In early 1989, the effect of combined water
bath HT and RT was published: higher cytotoxicity was ob-
served 24h after exposure to 43°C for 1h and single-dose
radiation at 5–10Gy compared to RT alone [26]. Moreover,
irradiation of 10Gy and microwave-induced HT at 44°C
for 1h were reported to significantly enhance cell death
of breast cancer cells 72h after treatment [27]. The de-
scribed effects of HT are intensively studied experimentally
in vitro and in vivo in a high variety of cancer models [21].
Nevertheless, the electromagnetic wave-based HT methods
lack reproducibility in target precision and heating capac-
ity, and do not allow the quantification of the thermal dose
through MR temperature mapping. Therefore, electromag-
netic wave-based HT is not accepted as a standard proce-
dure in clinical practice. Main challenges to establishing
HT are the invasiveness of temperature control techniques,
generation of uncontrollable heat spots, and focused heat-
ing with adequate penetration depth. Electromagnetic waves
cannot be focused as precisely as is possible with ultrasound
waves.
In contrast, ultrasound waves are mechanical waves gen-
erating heat through mechanical friction, which has the ad-
vantage of tissue penetration up to 20cm.When FUS propa-
gates through tissue or cells, the acoustic intensity decreases
as the energy of the wave is absorbed by the medium and
as a result, local heating occurs. FUS is the only nonin-
vasive technique in the thermal therapy field [28]. Besides,
the main advantage of FUS-induced HT is the precise treat-
ment planning under MRI guidance, which allows limited
heating in the target region without damage to surrounding
tissues. However, due to the lack of a reproducible in vitro
FUS system, only a few studies have reported combined
FUS and RT, and the biological effects and mechanisms
are not sufficiently investigated.
To translate the benefits of FUS-induced HT to support
RT, a certain number of experiments in vitro are required
to form the basis for preclinical in vivo studies. However,
studies regarding the interaction of FUS fields with cells
and comparative evaluation is difficult due to the lack of
a standardized technique for FUS delivery. On the other
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hand, the attenuation and absorption of acoustic energy are
much less in cell culture medium compared to soft tissues.
For instance, cancer cells were exposed to ultrasound in
centrifuge tubes in an in vitro study using a clinical HIFU
system [29]. The complicated handling of the clinical sys-
tem makes the experiment with various ultrasound param-
eters difficult. We developed a high-throughput laboratory
in vitro FUS system that mimics the principles of clinical
application, allowing the generation of FUS-induced HT in
a standard-size 96-well plate. Using the device can reduce
instrument-related variability in the results, improve the re-
producibility of acoustic fields, and facilitate the translation
of results to in vivo experiments and, ultimately, to medical
practices.
This study aimed to investigate the short-term radiosensi-
tizing properties of FUS-induced HT at the molecular level
with a newly developed in vitro experimental setup. The
impact of combination treatment including FUS and X-ray
irradiation on human glioblastoma, head and neck tumor,
and prostate cancer on cellular metabolic activity, induc-
tion of apoptosis, DNA double-strand breaks, and cell cycle
phase changes was investigated.
Methods
Tumor cell lines and cell culturing
Human glioblastoma cell line T98G was purchased from
American Type Culture Collection (ATCC) and LN405
from German Collection of Microorganisms and Cell Cul-
ture GmbH (DSMZ). Cells were cultured in Dulbecco’s
Modified Eagle’s Medium (DMEM, Gibco, Thermo Fisher
Scientific, Darmstadt, Germany). Human prostate cancer
cell line PC-3 was purchased from the European Collection
of Authenticated Cell Cultures (ECACC, Salisbury, UK)
and grown in Ham’s F-12K (Kaighn’s) medium (Gibco,
Thermo Fisher Scientific, Darmstadt, Germany). The head
and neck cancer cell line FaDu and UTSCC-8 (Onco-
Ray, National Center for Radiation Research in Oncology,
Dresden, Germany) were cultured in DMEM medium
supplemented with 2% HEPES (1M, PAA Laboratories,
Pasching, Austria), 1% sodium pyruvate (100mM, Sigma-
Aldrich GmbH, Munich, Germany), 1% MEM non-essen-
tial amino acids (100×, Sigma-Aldrich GmbH, Munich,
Germany). All cell culture media were supplemented with
10% (v/v) fetal bovine serum (FBS, Gibco, Thermo Fisher
Scientific, Darmstadt, Germany), 100U/mL penicillin, and
100mg/mL streptomycin (Biochrom GmbH, Berlin, Ger-
many) for culturing of the cell lines at 37°C in a humidified
incubator supplemented with 5% (v/v) CO2. For experi-
ments, cells were routinely washed with phosphate-buffered
saline (PBS, Biozym Scientific GmbH, Hessisch Oldendorf,
Germany), and detached using trypsin/EDTA (Biozym Sci-
entific GmbH, Hessisch Oldendorf, Germany). Cells used
in this experiment were in the exponential growth phase
and the passage number was less than 20. The cells were
negative for mycoplasma as routinely determined via PCR.
Focused ultrasound in vitro setup
The FUS in vitro system (Fig. 1a) consists of a Perspex box
with separate compartments for water where the ultrasound
transducer and the cell culture 96-well µClear plates are
placed. Deionized water was boiled for 5min and cooled
down to room temperature in a sealed container for de-
gassing [30]. Degassed water was circulated in the water
tank with a self-priming water pump (Lei Te Co., Ltd.,
Guangdong, China) to reduce ultrasound artifacts and pre-
vent air bubble formation underneath the plate. Temper-
ature was kept close to physiological levels at 34°C us-
ing an external heater (ETH 200, Hydor UK, Shropshire,
UK). The temperature was maintained 3°C lower than hu-
man body temperature to avoid neighbor overheating and
formation of air bubbles. To reach the target temperature
quickly, two transducers with frequencies of 1.142 and
1.467MHz at acoustic intensities of 213 and 225W/cm2
were chosen in this study to reach the target temperature
of 45°C (Fig. 1b, c). These two transducers are geometri-
cally focused with piezoceramic bowls (Meggitt-Ferroperm
Piezoceramics, Kvistgaard, Denmark). The focus points of
the transducers fit into the size of one well of the 96-well
plate, 6.96mm in diameter and 10.9mm in depth, when the
focus point is positioned at the bottom of the well (Sup-
plementary Table S1, Fig. S1). The acoustic intensities at
1.14 and 1.467MHz inside the well were calibrated with
hydrophone (Supplementary Table S2 and S3). The real-
time temperature in the wells during FUS treatment was
monitored using an infrared thermal camera PI450 (Optris
GmbH, Berlin, Germany) and imaging software (PI connect
version 2.10) with a feedback loop to the motor (VELMEX
Inc., Bloomfield, NY, USA) for the treatment of three non-
adjacent wells simultaneously.
As the thermal dose plays a major role in most hyper-
thermia research [31], the cumulative number of equivalent
minutes at 43°C (CEM43) in terms of the thermal dose
was used to quantify thermal exposure during treatment
(Table 1). It was calculated according to the equation pub-









0; if T < 39°C
0.25; if 39  T < 43°C




Fig. 1 The in vitro focused ultrasound (FUS) system. a For FUS exposure the ultrasound signal was generated by a piezoelectric focused transducer
immersed at the bottom of a tank filled with degassed water. The transducer is driven by a signal generator (Agilent 33120A) and an RF power
amplifier (Electronics and Innovation A075). Alongside the water bath, an X-Slide linear stage connected to a programmable motor controller
and a stepper motor (VELMEX NEMA 17) translates an attached Perspex holder carrying a cell culture well plate. The whole assembly slides
through the water above the transducer on two parallel aluminum tracks using small linear bearing carriages (Drylin N). A thermal camera monitors
temperature in real time inside the wells with a feedback loop to the linear stage to enable FUS in 3 wells in parallel. b The temperature generated
by the FUS transducer with frequency of 1.142MHz at intensity of 213W/cm2 to the mean temperature of 45.20± 2.29°C and c for frequency of
1.467MHz at intensity of 225W/cm2 to the mean temperature of 45.59± 1.65°C was measured by infrared thermal camera. The blue, black, and
red lines represented the real-time temperatures in three in-parallel sonicated wells
Table 1 Sonication duration per well and thermal dose
Frequency [Hz] Mean temperature [°C] Sonication duration per well [min] Thermal dose (CEM43)
1.142 45.20± 2.29 10.06± 0.80 436± 88
1.467 45.59± 1.65 10.18± 0.31 447± 79
Experimental protocol for in vitro focused
ultrasound treatment
Cells were cultured as described above and seeded into spe-
cial ultrasound-penetrable 96-well cell culture plates with
a 200µm thin foil µClear bottom (Greiner Bio-One Ltd,
Stonehouse, UK). FaDu and T98G cell lines at cell density
in a range of 2500–5000 cells/well, and PC-3 cells at cell
density in a range of 5000–10,000 cells/well were seeded in
the corresponding cell culture medium to reach 90–100%
confluency at the desired timepoint after treatment. The
seeding was performed 1 day prior to the FUS treatment.
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Before sonication, up to 420µL/well of cell culture medium
was added to each well and the plate was sealed with Titer-
tops (Electron Microscopy Sciences, Hatfield, PA, USA)
plate-sized US transparent films, avoiding air bubble for-
mation. The plate was placed in the FUS system using
the plate holder located above the transducer. FUS was
applied continuously for 30min at intensities of 213W/cm2
(1.147MHz) or 225W/cm2 (1.467MHz) to hold the tem-
perature stable at mean temperature of 45.20± 2.29°C
(1.147MHz) and 45.59± 1.65°C (1.467MHz; Fig. 1b, c)
for the FUS treatment. A nearly parallel sonication regime
was defined in MATLAB® based on the feedback from the
camera as follows: (1) move to the well with the lowest
temperature; (2) sonicate the well until its temperature
reaches the target temperature; (3) repeat until the length of
30min is reached. After sonication, the cells were observed
under optical microscopy, the entire volume of cell culture
medium was removed from the plate and refilled with
100µL/well fresh medium followed by incubation of cells
for a further 1–72h to investigate the short-term effects.
X-ray irradiation of cancer cell lines
Cells cultured in 96-well plates with corresponding cell
density in a range of 2500–10,000 cells/well were irra-
diated with a single dose using a 150kV X-ray machine
(DARPAC 150-MC, Raytec Inc., Swindon, UK) at a dose
rate of 1.276Gy/min. For determination of the non-lethal
radiation dose, radiation dose curves with 0 to 20Gy were
obtained. To quantify the cell proliferation after irradiation,
BrdU assay (Roche, Basel, Switzerland) was performed
96h post treatment. Based on the preliminary radiation dose
curves, a single dose of 10Gy was used in all combination
experiments (Supplementary Fig. S3).
Treatment protocol of combination of FUS and RT
The cancer cells were seeded in 96-well plates with
µClear bottom 24h before treatment at the density of
2500–10,000 cells/well in the corresponding culture
medium. The cells were first exposed to FUS-induced
hyperthermia as the protocol described above, followed by
single-dose X-ray irradiation at 10Gy with an interval time
of 60min (Fig. 2a). After treatment at respective endpoints,
cell metabolic activity, apoptosis, cell cycle distribution,
and DNA damage were evaluated.
Microscopic analysis andmeasurement of metabolic
activity
Cell morphology was analyzed by microscopy before and
after treatment (ZEISS Axio Observer, Carl Zeiss mi-
croscopy GmbH, Jena, Germany). To determine the short-
term impact of the different treatments on the metabolic
activity of the human cancer cell lines, the tetrazolium
salt-based metabolic activity assay WST-1 (Roche, Basel,
Switzerland) was performed 24, 48, and 72h after treat-
ment. According to the manufactures’ instructions, the
medium was discarded and cells were incubated with fresh
cell culture medium including WST-1 reagent (final 10%)
in the 96-well µClear cell culture plates. The absorbance
at 435nm was measured using a plate reader (Synergy H1,
BioTek, Bad Friedrichshall, Germany).
Annexin V-FITC assay
To detect apoptotic and necrotic cells an annexin V-FITC
assay (Cayman Chemical, Ann Arbor, MI, USA) was per-
formed 4, 24, and 72h post treatment according to the man-
ufacturers’ instructions. In brief, the staining solution was
prepared freshly by mixing annexin V-FITC (1:500) and
propidium iodide (PI, 1:2000) with binding buffer. 50µL
staining solution was added to each well and incubated at
room temperature for 10min in the dark, centrifugation for
5min at 400g was performed afterwards. Finally, staining
solution was discarded and 100µL binding buffer was added
to each well followed by fluorescence microscopy using
ZEN 2.3 software (ZEISS Axio Observer, Carl Zeiss mi-
croscopy GmbH, Jena, Germany). Apoptotic cells stained
with annexin V-FITC were detected at excitation/emission
maxima at 485/535nm and PI-stained dead cells at excita-
tion/emission maxima at 535/617nm. Flow cytometry (At-
tuneNxT, Thermo Fisher Scientific, Darmstadt, Germany)
was used additionally to quantify the number of stained
cells.
Cell cycle analysis and apoptosis detection
The effects of FUS and RT on apoptosis-induced DNA
fragmentation and cell cycle phase distribution were in-
vestigated by Nicoletti assay [33] using flow cytometry 4,
24, and 72h after treatment. Briefly, cells were trypsinized
from 96-well plates with 100µL trypsin/EDTA per well and
harvested into one 1.5ml reaction tube, washed twice with
PBS, and fixed with 70% ethanol at –20°C overnight. Cells
were washed again twice with PBS and incubated with
60µL RNaseA solution (Sigma-Aldrich GmbH, Munich,
Germany) at a final concentration of 0.1mg/mL at 37°C
for 20min. Afterwards, the DNA content was stained by
propidium iodide (PI, Sigma-Aldrich GmbH, Munich, Ger-
many) at a final concentration of 50µg/mL at 4°C for 5min
and cells were assessed by flow cytometry (AttuneNxT,
Thermo Fisher Scientific, Darmstadt, Germany).
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Fig. 2 The combination of FUS and RT (10Gy) decreases the cell metabolic activity in a time-dependent manner. Cancer cell lines were treated
with the FUS in vitro system at mean temperature of 45°C for 30min followed by irradiation of 10Gy 60min later in the combination groups.
a The experimental timing scale describes the treatment procedure in the FUS and RT combination group. b Relative cellular metabolic activity was
measured by WST-1 assay. Data were normalized to the untreated control, which was set as 100%. c Representative microscopy images showing
alterations in cell morphology 72h after treatment. Scale bar= 50µm. d Quantification of observed cell aspect ratio 72h after treatment. Data are
presented as mean± SD. N= 9, significantly different from untreated control (*p≤ 0.05), significantly different from RT (#p≤ 0.05). FUS focused
ultrasound, RT radiation therapy
K
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Detection of DNA double-strand breaks
To determine DNA double-strand breaks (DSBs), γH2A.X
assay was performed 1 and 24h post treatment. The cell cul-
ture medium was aspirated from each well, and cells were
fixed with 4% formaldehyde at 37°C for 10min, chilled
on ice for 1min, the fixative was removed, and cells were
washed three times with 1× PBS. Cells were permeabilized
with 90% methanol on ice for 30min, and again washed
three times with PBS. Non-specific antibody binding was
blocked by 0.5% bovine serum albumin (BSA, Cell Sig-
nalling Technology, Danvers, MA, USA, 100µL/well) in
PBS at room temperature for 10min. After removing the
block solution (0.5% BSA in PBS), cells were incubated
with 50µL/well phospho-histone H2A.X (Ser139) rabbit
primary monoclonal antibody (#9718, Cell Signalling Tech-
nology, Danvers, MA, USA) at a concentration of 1:400
diluted with block solution at room temperature for 1h.
Cells were washed three times with antibody-free BSA so-
lution and incubated with 50µL/well secondary antibody
(anti-rabbit IgG conjugated with Alexa Fluor® 594 fluores-
cent dye; #8889, Cell Signalling Technology, Danvers, MA,
USA) at a concentration of 1:1000 diluted with block solu-
tion at room temperature in the dark for 30min. Cells were
finally washed three times with block solution and mounted
with Fluoromount-GTM (Thermo Fisher Scientific, Darm-
stadt, Germany) including DAPI to stain cell nuclei. DNA
double-strand breaks were visualized at excitation/emission
at 561/594nm and blue nuclei at 358/461 using fluorescence
microscopy. The mean numbers of stained foci per cell nu-
cleus were semi-quantitatively analyzed by ImageJ software
Find Maxima tool, counting all nuclei (80–120 nuclei) in
the images.
Statistical analysis
Statistical analysis was performed using the statistical pro-
gram Origin (Origin 6.0, OriginLab, Northampton, Mas-
sachusetts, USA). All data of metabolic activity (WST-1
assay), cell cycle (PI), and DNA double-strand breaks
(γH2A.X) are expressed as means± standard deviation of
three independent experiments with three replicates. The
significance of difference between two mean values was
assessed by one-way ANOVA test. A p-value≤ 0.05 was
considered to be statistically significant.
Results
Effective combination of FUS and RT leads to
reduction in metabolic activity and morphologic
changes in glioblastoma and prostate cancer cells
To evaluate the short-term effects on cancer cell morphol-
ogy and metabolic activity after combination of FUS and
RT treatments, cell morphology and cellular metabolic ac-
tivity were evaluated 24, 48, and 72h post treatment. The
combination of FUS and RT did not affect cell metabolic
activity of T98G cells significantly at 24h, whereas a signif-
icant decrease was observed in FaDu (95.28± 4.74%) and
PC-3 (85.82± 16.44%) cells compared to untreated con-
trols. A significant reduction (p≤ 0.05) of metabolic ac-
tivity compared to RT alone was observed in T98G cells
from 96.47± 8.29% (RT only) to 79.38± 14.93% (FUS+RT;
48h) and in PC-3 cells from 54.20± 10.85% (RT only) to
41.01± 11.17% (FUS+RT; 72h; Fig. 2b, red arrow). In con-
trast, no significant changes of metabolic activity in FaDu
cells were noticed at 48 and 72h in the FUS+RT group
compared to RT alone. FUS alone only showed a notable
effect on metabolic activity in FaDu cells (91.45± 6.55%)
at 24h and in PC-3 cells (75.49± 26.61%) at 72h com-
pared to untreated controls, the effect was not observed in
T98G cells. A typical cobblestone-like phenotype was ob-
served in all cell lines after ionizing radiation (Fig. 2c).
As demonstrated by quantification of morphology, the cell
aspect ratio was significantly reduced in the RT-only and
FUS+RT group 72h after treatment compared to the control
group (Fig. 2d).
Combination of FUS and RT triggers programmed
cell death
Next, we explored whether thermal effects induced with
FUS and the combination of FUS and RT are able to cause
apoptosis detected via annexin V-FITC/PI. Representative
fluorescence microscopy images revealed no apoptotic or
necrotic events in the untreated control (Fig. 3a). FUS alone
and RT alone induced only a small number of early (green,
annexin V+/PI–) and late apoptotic cells (green and red,
annexin V+/PI+). A higher number of late apoptotic cells
(annexin V+/PI+) was noticed after combination of FUS
and RT compared to RT alone 72h post combination treat-
ment, especially in T98G and PC-3 cells. Only a few or no
necrotic cells (annexin V–/PI+) were observed in FaDu,
T98G, and PC-3 cells at this timepoint. To quantify apop-
totic rates after treatment, the annexin V-FITC/PI staining
was analyzed by flow cytometry in a single experiment
72h after treatment. The combined FUS and RT treatment
(Fig. 3b) showed early apoptotic levels higher by 1.4-fold
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Fig. 3 Combination of FUS and
RT (10Gy) enhances apoptotic
rate in PC-3 cells. a Representa-
tive fluorescence microscopy
images showing single an-
nexin V-FITC-stained (green)
early apoptotic cells (trian-
gle a) and single PI-stained
(red) necrotic cells (triangle b).
Double staining indicates late
apoptotic cells (white arrows).
Scale bar= 100µm. b Quanti-
fied flow cytometric analysis of
annexin V-FITC/PI was shown
72h post treatment, early apop-
tosis and total apoptosis are
given as percentage of total
cells (*p≤ 0.05, significantly
different from RT). FUS focused
ultrasound, RT radiation therapy
in FaDu cells, by 1.5-fold in T98G, and by 1.6-fold in PC-3
compared to RT alone.
Combination of FUS and RT leads to an increase in
apoptosis and G2 phase arrest
To determine the potential role of FUS as a radiosensi-
tizer, the cell cycle phase distribution of cancer cells and
the apoptotic sub-G1 fraction indicating apoptotic cells was
measured 4, 24, and 72h after treatment. Compared to the
untreated control and FUS alone, the sub-G1 phase cell
population was significantly enhanced after RT alone and
further enhanced after combined FUS+RT in all three cell
lines 72h post treatment (Table S4). In comparison to un-
treated controls, a dramatic increase of the sub-G1 popu-
lation was observed after combined FUS+RT, by 6.3-fold
in FaDu after 72h, 3.8-fold in T98G after 24h, and 4.4-
fold in PC-3 after 72h. Compared to RT alone, the sub-G1
fraction was increased by 1.3-fold, 1.8-fold, and 1.6-fold,
respectively.
Changes in cell cycle phase distribution were observed,
showing an increased sub-G1 population with a subsequent
reduction of G0/G1 cells by approximately 30% in all cell
lines after RT and FUS+RT compared to the untreated con-
K
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Fig. 4 FUS and RT (10Gy) combination impacts sub-G1 and G2/M cell cycle phase. a Representative flow cytometry cell cycle measurements
24 or 72h post treatment. Depending on different doubling times of the cell lines, different timepoints after treatment are shown in the diagrams.
b Graphical representation of the cell cycle distribution of FaDu, T98G, and PC-3 cells under control conditions and in response to treatment 24 or
72h post treatment. Cell populations in sub-G1, G0/G1, S, and G2/M phases are given as percentage of total cells (*p≤ 0.05, significantly different
from control; #p≤ 0.05, significantly different from RT). FUS focused ultrasound, RT radiation therapy
trol. FUS alone showed no significant impact on cell cycle
distribution at different timepoints for any cell lines. No
regulation of S phase was seen in any single or combi-
nation treatment group. The percentage of cells in G2/M
phase was enhanced 1.4-fold in FaDu, 3.6-fold in T98G,
and 1.4-fold in PC-3 after FUS+RT treatment compared to
untreated controls (Fig. 4b). Interestingly, the populations
of T98G and FaDu cells in G2 phase decreased dramatically
at 72h compared to 24h after RT; however, this reduction
was not observed in PC-3 cells (Supplementary Table S2).
Increase of DNA double-strand breaks after
combined FUS and RT
DSBs were employed to explore the potential of FUS to af-
fect DNA repair mechanisms by scoring the γH2A.X foci 1
and 24h post treatment (Fig. 5, Table S5). Representa-
tive fluorescence microscopy images of stained γH2A.X
foci showed the highest number of stained initial (1h) and
residual (24h) foci in all cell lines in the combination
group (FUS+RT) (Fig. 5a, red foci). All cell lines revealed
only a limited number of DSBs in the untreated control at
low levels ranging from 0.75 to 1.6 foci/nucleus (Fig. 5b).
Similar numbers of initial γH2A.X foci per cell were de-
tected after FUS alone in FaDu cells (2.12 foci/nucleus) and
PC-3 cells (2.19 foci/nucleus). In contrast, a higher initial
γH2A.X number was observed in T98G cells (10.21 foci/
nucleus) in the FUS-only treatment group. In comparison to
RT alone, significantly higher numbers of initial foci were
measured in T98G (1.4-fold) and PC-3 (1.8-fold) cells af-
ter the combination of FUS and RT. The residual foci were
scored 24h post treatment, and displayed similar results
with a slight reduction compared to initial foci number. Nei-
ther initial nor residual foci enhancement was observed in
FaDu cells after FUS+RT treatment compared to RT alone.
Discussion
Regarding the translation of the combined FUS and RT ef-
fect found in this in vitro study to the clinical situation, we
first want to mention that the applied frequency range of
1.0 to 1.5MHz is reasonable, since most of the clinically
approved HIFU and FUS platforms provide frequencies of
0.8–1.5MHz for body applications including, e.g., ablation
of uterine fibroids and bone metastasis [3, 34]. Moreover,
the clinically available HIFU-HT platform Sonalleve (Pro-
found medical, Canada) works in the described frequency
range [35]. Lower frequencies ≤0.5MHz which are, e.g.,
applied by Exablate (Insightec, Israel) for blood–brain bar-
rier opening [36] or higher frequencies like 3MHz used in
the Echopulse system (Theraclion, France) have only a lim-
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Fig. 5 Combination of FUS and
RT (10Gy) enhanced the number
of DNA double-strand breaks
compared to single treatment.
a Representative microscopy im-
ages showed more γH2A.X foci
(Alexaflour568 red) in the cell
nucleus (blue) after combination
treatment (FUS+RT) compared
to single FUS and single RT
treatments. Scale bar= 10µm.
b Quantification of γH2A.X foci
1h and 24h after treatment. The
data represent the mean± SD,
n≥ 6, *significantly different
from RT (p≤ 0.05). FUS focused
ultrasound, RT radiation therapy
ited penetration depth [37] and would thus not be suitable
for flexible applications in clinical use cases.
Use of a normal polystyrene 96-well plate is not advis-
able for studying the effects of FUS in vitro, because the
FUS beams cannot penetrate but are even absorbed and re-
flected by the plastic parts. Therefore, special cell culture
plates should be used which have a sufficiently thin foil
bottom for transfer of the FUS waves to the cells.
The response of cancer cells to combination treatment
with HT and RT is dependent on time interval and treatment
sequence [38]. As reported in a clinical study, a short time
interval (≤79.2min) displayed significantly higher 5-year
survival compared to the long time interval group [39]. With
a short interval time of 1h, the beneficial effects were simi-
lar in cancer cells regardless of the treatment sequence [40].
Due to the practical transportation, the FUS treatment was
performed before RT with an interval time of 60min in our
study.
Since HT-induced cytotoxicity and DNA damage can be
observed during 24h and these effects can be recovered by
time as reported in the literature [41, 42], it is essential to
evaluate the cell metabolic activity with same time scale.
In contrast, clonogenic assay, which is typically used in ra-
diation research, measures the reproductive cell death by
assessing the long-term effect after 2–3 weeks [43]. There-
fore, cell metabolic activity was measured within 72h for
investigation of short-term biological effects.
Interestingly, no significant changes were detected on
cellular metabolic activity and morphology after the FUS
alone treatment. That reveals that FUS at temperatures in
a range of 43–47°C has no cytotoxic effects, indicating that
FUS waves do not lead to structural damage or detachment
of monolayer cells, even if the thermal dose CEM43 is over
400. Brüningk et al. [44] reported that high-temperature HT
induced by PCR thermal cycler at 47°C (CEM43 up to 700)
reduced cell viability by approximately 40% in CAL27 cells
(squamous cell carcinoma cell line) if the thermal dose was
above 350. FUS treatment induces the thermal effects by
mechanical waves, which is different to the PCR thermal
cycler and may consequently result in different biological
effects. The temperature curve of a PCR thermal cycler is
more stable compared to the FUS treatment in our study,
which shows rapid temperature fluctuations. During FUS
treatment, the temperature changed very fast due to the
movement of 96-well plate; therefore, the cells cannot be
exposed to the maximum temperature of 48°C for a long
duration, but the thermal dose was dramatically increased
in our case. In addition, cells treated by PCR thermal cy-
cler were often in suspension; however, cancer cells are
more sensitive to heat treatment in suspension compared
to monolayer [45]. Further investigations of FUS regarding
different heat induction mechanisms and heating profiles
are required in comparison to conventional HT.
The typical cobblestone-like shape of cells was induced
mainly by ionizing radiation [46]; the combination of FUS
and RT did not lead to significant morphologic changes
in the cell aspect ratio compared to RT alone. The signifi-
cant reduction of cell metabolic activity post FUS+RT treat-
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ment in comparison to the RT-only group indicates radio-
additive effects of FUS for the investigated glioblastoma
and prostate cancer cell lines. This finding is in accordance
with a study of McDonald et al., who previously reported
about an additive effect on glioblastoma cells when modu-
lated electro-HT was combined with X-ray radiation [47].
No reduction of metabolic activity was seen in the head
and neck cancer cell line FaDu, displaying an overall lower
sensitivity of this tumor cell line to combined FUS and RT
treatment. In this context, a relatively high resistance of
head and neck tumors to radiotherapy is reported in the lit-
erature [48]. In the clinic, this circumstance is still a major
cause of poor survival rates after RT of head and neck tu-
mors, revealing the need for radiosensitization of this tumor
entity.
After HIFU ablation treatment, the tissues are typically
in a necrotic state and need to be cleared by the body, which
may cause inflammation [49]. Therefore, programmed cell
death (apoptosis) avoiding tissue coagulation and necrotic
events is preferred using temperatures below 50°C. No-
tably, higher numbers of early and late apoptotic cells and
the sub-G1 phase cell population were observed 72h post
combination treatment in T98G and PC-3 cells compared
to RT alone. The higher number of apoptotic cells after
FUS+RT indicates the additive effects of FUS to support
RT. In addition, no necrotic cells were noticed, illustrating
that necrosis is a rare event after treatment at 72h. More-
over, fragmentation of DNA is described as a hallmark of
apoptosis [50] and was visualized by the sub-G1 peak in
the histograms, confirming the results of the annexin V as-
say. In general, HT has been reported in numerous studies
to induce programmed cell death [51], thus enhancing ra-
diosensitivity. Nevertheless, it is possible in our study that
the temperature fluctuations in the 96-well plates during the
FUS in vitro treatment with the current setup led to only
a few apoptotic events. These differences between heating
processes may have an impact on apoptosis and do not in-
duce detectable apoptosis with FUS alone. Whether this
effect is responsible for the differences in sensitivity to RT
of the various cell lines or if the anti-cancer effect of FUS
could be enhanced in FaDu with more stable temperatures
over time remains to be investigated.
The success of irradiation is mainly caused by damage
of DNA ending in apoptotic catastrophe [24]. Generally, it
is known that RT of cells prolongs the G1 and G2 phase
to repair induced DNA damage [43, 52, 53]. Here, the cell
population in G2/M phase increased in the RT alone and
FUS+RT groups, but not in the FUS-only group, indicat-
ing an RT-induced G2 phase arrest in all cell lines. The
significant recovery of FaDu and T98G cells in G2 phase
probably demonstrates the occurrence of complete DNA re-
pair with progression of the cell cycle or induction of cell
death, respectively. On the contrary, no complete recovery
was noticed in PC-3 cells, implying a slightly higher ra-
diosensitivity of this prostate cancer cell line compared to
the other used cell lines or a prolonged time for DNA repair
in PC-3. In the context of prolonged G1 and G2 phases, it
needs to be noted that wildtype p53 protein is required for
G1 phase arrest and apoptosis [54]. Since only human p53-
mutant cancer cell lines were used in this study, an arrest
in G1 was not expected.
The increase of direct DNA damage as DSBs was dis-
played as the foci number of the phosphorylated histone
protein H2A.X (γH2A.X), while histone phosphorylation
is the first marker of DNA DSBs [55]. Combination of
FUS and RT leads to significant enhancement of initial and
residual foci in T98G and PC-3 cells compared to RT alone,
highlighting the radiosensitization effects of FUS. The sig-
nificantly higher numbers of initial foci in T98G and PC-
3 cells are probably caused by the inhibition and damage
of DNA repair proteins [41]. Regarding detection of a lim-
ited recovery of foci in the RT and FUS+RT groups, we
hypothesize that these DSBs are difficult to repair or re-
main unrepaired unless the cells die [56]. The pan-γH2A.X
signal indicated the damage of S-phase cells after combi-
nation treatment. S-phase cells are hypersensitive to heat-
induced killing, as reported by Wong [57]. The DNA DSBs
of S-phase cells occur due to the encounter of DNA replica-
tion forks with single-strand breaks [58]. When the breaks
were not repaired, persistent DNA damage signal were de-
tected. Only a few increases in foci were observed in the
head and neck cell line after FUS+RT treatment compared
to RT alone, illustrating that the radio-additive effects are
cell type dependent. This finding in DSBs is supposed to be
the reason for no reduction in the cellular metabolic activity
in FaDu cells. The potential molecular mechanism may ex-
plain the different reaction of FaDu cells. Epidermal growth
factor receptor (EGFR) is overexpressed in head and neck
cell lines, ionizing radiation induces translocation of EGFR
into the nucleus [59] and leads to activation of PI3K and
RAS pathway, which supports proliferation and survival of
head and neck tumor cells. Additionally, translocation of
EGFR may result in increased repair of radiation-induced
DSBs and consequently increase the radioresistance of head
and neck cells [60]. Therefore, the results indicate that ra-
diosensitization events induced by FUS are not a general
phenomenon, a finding that is in accordance with previous
reports [61, 62]. Potential mechanisms in molecular level
need further investigation.
Notably, application of FUS treatment alone demon-
strated no impact on cell metabolic activity, apoptosis, cell
cycle distribution, and DNA damage, indicating that FUS
in the applied temperature range is not a lethal treatment
modality but can cause sensitization of tumor cells to RT.
Chae et al. reported that HIFU-induced HT at 42–43°C for
40min could be tolerated by mice and showed a limited
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impact on tumor growth compared to the untreated control
group [63].
Radiosensitizing effects of HT are still discussed contro-
versially in the clinic. A clinical phase II study in prostate
cancer patients showed a significant improvement in sur-
vival rates after combination of transrectal ultrasound HT
at 42°C and RT compared to RT alone [64]. In contrast,
a randomized trial in head and neck cancer patients demon-
strated no significant differences in tumor response when
HT was used as adjuvant therapy for RT [65]. This is impor-
tant as it reflects different sensitivities to the combination
of HT and RT depending on the tumor entities.
We provide a standard FUS treatment system for in vitro
study and some general observations regarding the molec-
ular mechanism of FUS were made. However, there are
several limitations in our study due to practical aspects.
To measure the temperature inside the wells without per-
turbing the ultrasound field during the FUS treatment, an
infrared thermal camera was used, as the usually applied
metal thermocouples are known to disrupt the US field and
lead to unnatural heating at the thermocouple surface [66].
As a compromise for temperature measurement, the ultra-
sound waves are reflected at the medium–air interface and
the standing waves in our experimental setup were simu-
lated (Supplementary Fig. S2). Moreover, cavitation events
initiate at pressures above 0.7MPa at 0.74MHz, according
to the report of Giesecke et al. [67]. Since the cell culture
medium was not degassed, cavitation events might occur
during FUS exposure and have potential biological effects
on cancer cells.
Since HT has been reported in vivo and in clinical set-
tings to sensitize tumor cells to RT by reducing tumor hy-
poxia and increasing tumor perfusion [21, 68], these com-
plex processes cannot be depicted in an in vitro study; here
are the limits of our preclinical study presented in this work.
Conclusion
Our study with the in vitro FUS experimental setup demon-
strated that combination of FUS-induced HT and RT re-
sulted in a significant radiosensitization effect seen in the
reduction of metabolic activity based on the enhancement
of apoptosis levels and DNA double-strand breaks found in
the human glioblastoma cell line T98G and prostate can-
cer cell line PC-3. Our results suggest that FUS treatment
alone does not harm cancer cells and has great potential to
enhance the effects of RT. This is currently being further
investigated in vivo.
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